Léo Mas

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Jean‐Baptiste Bachet · 10 shared papers, 2020–2026 · strength 2.01
   • Paper €2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France. DOI 10.1016/j.clinre.2026.102873↗
   • Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
   • Paper Nationwide trends over 10 years in epidemiology and management of pancreatic ductal adenocarcinoma: A real-world study … DOI 10.1016/j.clinre.2024.102426↗
2. David Piquemal · 2 shared papers, 2024–2026 · strength 0.61
   • Paper €2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France. DOI 10.1016/j.clinre.2026.102873↗
   • Paper Nationwide trends over 10 years in epidemiology and management of pancreatic ductal adenocarcinoma: A real-world study … DOI 10.1016/j.clinre.2024.102426↗
3. Rémy Nicolle · 3 shared papers, 2023–2026 · strength 0.57
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
   • Paper Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2023.102108↗
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
4. Jean‐Luc Van Laethem · 3 shared papers, 2023–2026 · strength 0.57
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
   • Paper Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2023.102108↗
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
5. Shulin Zhao · 3 shared papers, 2020–2026 · strength 0.49
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
   • Paper Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up:… DOI 10.1016/j.ctrv.2020.102028↗
6. Julie Navez · 2 shared papers, 2024–2026 · strength 0.38
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
7. Pieter Demetter · 2 shared papers, 2024–2026 · strength 0.38
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
8. Nicky D’Haene · 2 shared papers, 2024–2026 · strength 0.38
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
9. Christelle Bouchart · 2 shared papers, 2024–2026 · strength 0.38
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
   • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
10. Matthieu Hein · 2 shared papers, 2024–2026 · strength 0.38
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
11. Oier Azurmendi Senar · 2 shared papers, 2024–2026 · strength 0.38
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
12. Kosta Stosic · 2 shared papers, 2024–2026 · strength 0.38
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
13. Ilse Rooman · 2 shared papers, 2024–2026 · strength 0.38
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
14. Tatjana Arsenijevic · 2 shared papers, 2024–2026 · strength 0.38
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Ster… DOI 10.1101/2024.04.30.591890↗
15. Pierre Laurent‐Puig · 2 shared papers, 2020–2025 · strength 0.38
    • Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
    • Paper Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up:… DOI 10.1016/j.ctrv.2020.102028↗
16. Daniel Pietrasz · 2 shared papers, 2020–2025 · strength 0.38
    • Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
    • Paper Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up:… DOI 10.1016/j.ctrv.2020.102028↗
17. Honorat Agbeci · 1 shared paper, 2026 · strength 0.36
    • Paper €2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France. DOI 10.1016/j.clinre.2026.102873↗
18. Magali Svrcek · 2 shared papers, 2021–2023 · strength 0.35
    • Paper Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2023.102108↗
    • Paper Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review o… DOI 10.3390/ijms22136756↗
19. Jerome F. Cros · 2 shared papers, 2021–2023 · strength 0.35
    • Paper Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2023.102108↗
    • Paper Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review o… DOI 10.3390/ijms22136756↗
20. Olivier Caliez · 1 shared paper, 2025 · strength 0.27
    • Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
21. Mathilde Wagner · 1 shared paper, 2025 · strength 0.27
    • Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
22. Solène Doat · 1 shared paper, 2025 · strength 0.27
    • Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
23. Ellis Michiels · 1 shared paper, 2026 · strength 0.22
    • Paper Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-… DOI 10.1038/s41416-025-03274-0↗
24. Raëf Abdallah · 2 shared papers, 2020–2021 · strength 0.21
    • Paper Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up:… DOI 10.1016/j.ctrv.2020.102028↗
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
25. Julien Taı̈eb · 2 shared papers, 2020–2021 · strength 0.21
    • Paper Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up:… DOI 10.1016/j.ctrv.2020.102028↗
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.